SavedAdd your journal

Journals / Cumhuriyet Science Journal / 2021 / Cilt: 42 - Sayı: 4

Effects of EGFR inhibitor AG 1478 on MDA-MB-231 and MCF-7 breast cancer cells

Nazlıcan İŞLEN
Mehmet Rıfkı TOPÇUL
Pages
758–765
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There were significant differences between the control and the experimental groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this current study, antiproliferative effect of EGFR inhibitor AG1478 was investigated in human breast cancer cell lines.
📊
Key Findings & Data:MDA-MB-231 and MCF-7 cell lines were used respectively as triple negative breast cancer and Luminal A breast cancer model.
💡
Conclusion & Impact:There were significant differences between the control and the experimental groups (p
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this current study, antiproliferative effect of EGFR inhibitor AG1478 was investigated in human breast cancer cell lines. MDA-MB-231 and MCF-7 cell lines were used respectively as triple negative breast cancer and Luminal A breast cancer model. To this end cell viability, cell index values by xCELLigence Real Time Cell Analysis DP instrument and mitotic index analysis were used. The results of the current study showed that AG1478 had cytostatic effects on both of cell lines. The IC50 concentration was determined as 50 µM for MDA-MB-231 and 20 µM for MCF-7 cell line. IC50 concentration was used for mitotic index parameter. IC50 concentrations decreased the mitotic index values of both of cell lines. There were significant differences between the control and the experimental groups (p

🔖

Cite This Article

İŞLEN, N., TOPÇUL, M. R. (2022). Effects of EGFR inhibitor AG 1478 on MDA-MB-231 and MCF-7 breast cancer cells. Cumhuriyet Science Journal, Cilt: 42 - Sayı: 4, 758–765. https://ajindex.com/articles/477564

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Russo J., Russo I.H., Development of The Human Breast, Maturitas, 49(1) (2004) 2-15
  2. Bahreyni A., Samani S.S., Rahmani F., Behnam Rassouli R., Khazaei M., Ryzhikov M. et al., Role of Adenosine Signaling in The Pathogenesis of Breast Cancer, Journal of Cellular Physiology, 233(3) (2018) 1836-1843
  3. Topçul M., Çetin İ., Breast Cancer, Cancer: Disease of the Age, In: (Ed.) Ahmed M El Sharkawy, Chapter 19, OMICS Group eBooks, Foster City, USA, (2015) 1-21
  4. Board P.C.G.E., Genetics of Breast and Gynecologic Cancers (PDQ®), (2016)
  5. Schulz W.A., Breast Cancer, In: Schulz WA (Ed.). Molecular Biology of Human Cancers, Springer, Germany, (2005) 357-382
  6. Weber G.F., Epithelial Tumors, In: Weber GF (Ed.). Molecular Mechanisms of Cancer, Springer, USA, (2007) 441-524
  7. Tryggvadottir L., Olafsdottir E.J., Gudlaugsdottir S., Thorlacius S., Jonasson J.G., Tulinius H. et al., BRCA2 Mutation Carriers, Reproductive Factors and Breast Cancer Risk, Breast Cancer Research, 5(5) (2003) R121
  8. Narod S.A., Modifiers of Risk of Hereditary Breast and Ovarian Cancer, Nat. Rev. Cancer, 2 (2002) 113-123
  9. Vidarsson H., Mikaelsdottir E.K., Rafnar T., Bertwistle D., Ashworth A., Eyfjord J.E. et al., BRCA1 and BRCA2 Bind Stat5a and Suppress Its Transcriptional Activity, FEBS Letters, 532(1-2) (2002) 247-252
  10. Yarden Y., Ullrich A., Growth Factor Receptor Tyrosine Kinases, Annu Rev Biochem., 57 (1988) 443-478
  11. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R. et al., Epidermal Growth Factor Receptor (EGFR) Signaling in Cancer, Gene, 366(1) (2006) 2-16
  12. Demirelli F.H., Hedefe yönelik kanser tedavisi ve monoklonal antikorlar, Antibiyotik ve Kemoterapi Derneği (ANKEM) Dergisi, 19 (2005) 123-125
  13. Mehrabi M., Mansouri K., Soleymani B., Hoseinkhani Z., Shahlaie M., Khodarahmi R., Development of A Human Epidermal Growth Factor Derivative with EGFR-Blocking and Depleted Biological Activities: A Comparative In Vitro Study Using EGFR-Positive Breast Cancer Cells, International Journal of Biological Macromolecules, 103 (2017) 275- 285
  14. Cadena D.L., Gill G.N., Receptor Tyrosine Kinases, FASEB J., 6 (1992) 2332-2337
  15. Pawlowski V., Revillion F., Hebbar M., Hornez L., Peyrat J.P., Prognostic Value of The Type I Growth Factor Receptors in A Large Series of Human Primary Breast Cancers Quantified with A Real-Time Reverse Transcription polymerase Chain Reaction Assay, Clin. Cancer Res., 6 (2000) 4217-4225
  16. Gullick W.J.,